Pancreatic cancer is feeling the heat.

adenocarcinoma combination therapy gastrointestinal cancer immunotherapy tumor microenvironment - TME

Journal

Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585

Informations de publication

Date de publication:
28 Oct 2024
Historique:
accepted: 12 10 2024
medline: 29 10 2024
pubmed: 29 10 2024
entrez: 28 10 2024
Statut: epublish

Résumé

Pancreatic adenocarcinoma (PDAC) is considered an immunologically 'cold' tumor that fails to attract or support effector T cells. Most PDACs are resistant to immune checkpoint blockade due to the complex signaling pathways that exist within its tumor microenvironment. Recent advances in genomic and proteomic technology advances are finally uncovering the complex inflammatory cellular and intercellular signals that require modulation and reprogramming. The goal is to 'turn up the heat' on PDACs with combination immunotherapies that incorporate T cell activating agents and immune modulatory agents, and successfully eradicate tumors. Here, we discuss progress and promising new research that is moving the field toward this goal.

Identifiants

pubmed: 39467640
pii: jitc-2024-010124
doi: 10.1136/jitc-2024-010124
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: EMJ reports other support from Abmeta and Adventris, personal fees from Dragonfly, Neuvogen, CPRIT, Surge Tx, Mestag, Medical Home Group, HDTbio, and grants from Lustgarten, Genentech, BMS, NeoTx, and Break Through Cancer. EMJ is the Dana and Albert 'Cubby' Broccoli Professor of Oncology.

Auteurs

Saumya Y Maru (SY)

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Convergence Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Bloomberg Kimmel Immunology Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
The Skip Viragh Center for Clinical and Translational Research, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Elizabeth M Jaffee (EM)

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA ejaffee@jhmi.edu.
Convergence Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Bloomberg Kimmel Immunology Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
The Skip Viragh Center for Clinical and Translational Research, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH